An observational study in Limb; Fusion and Complication, sponsored by Henan Cancer Hospital. Not yet recruiting at 1 site in China. Per ClinicalTrials.gov, last updated 2024-01-18.
Sponsored by Henan Cancer Hospital · Observational
To report the postoperative complications and limb function of patients with osteolysis after surgery for bone tumors of the extremities who received anti-osteoporosis therapy in Henan Cancer Hospital in the next 10 years.
A total of 100 patients with osteolysis after surgery for bone tumors of the four extremities who received anti-osteoporosis treatment in Henan Cancer Hospital in the next 10 years were reported. The basic information, treatment methods, postoperative complications and limb function of these patients were collected.
Henan Cancer Hospital is the lead sponsor of 228 studies on the registry; 130 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients receiving antiosteoporosis therapy for osteolysis after surgery for bone tumors in the extremities
Exclusion Criteria:
Not applicable.
Patients who received antiosteoporosis therapy after bone tumor resection
Other: Anti-osteoporosis therapy
Patients who underwent bone tumor resection without antiosteoporosis therapy
Bone healing, limb function, and complications of postoperative osteolysis in patients with bone tumors of the extremities treated with anti-osteoporosis therapy.
Complications
The incidence of complications after anti-osteoporosis treatment was collected and the severity of complications was evaluated according to CTCAE5.0.
Time frame: Collected from the beginning of treatment to 24 months after treatment.
Limb function
Limb function was assessed using the Musculoskeletal Oncology Society (MSTS) scoring scale for seven items, namely movement, pain, stability, deformity, strength, functional activity, and emotional receptiveness. The highest possible score is 35, with 5 points allocated to each project.
Time frame: Collected from the beginning of treatment to 24 months after treatment.
Plan to share: No
No publications or documents are linked to this record.
This study is not yet recruiting, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Henan Cancer Hospital